In the development of biotherapeutics, a thorough understanding of a molecule’s product quality attributes (PQAs), and their effect on structure-function relationships and long-term stability, is key for ensuring the safety/efficacy of the product. At present, numerous routine chromatographic and electrophoretic assays are used to characterize and monitor individual PQAs for batch release, stability time-points and process/formulation development support. However, execution of multiple routine methods is time/resource intensive and often provides an indirect measure of biologically-relevant PQAs. Learn about an MS-based multi-attribute method (MAM) “Lab-of-the-Future,” that provides concurrent detection, identification, quantitation and quality control (monitoring) of PQAs.

About the presenter

Andrew Dawdy, Principal Scientist, Pfizer

Andrew Dawdy, Principal Scientist, Pfizer

Andrew received his PhD in Chemistry from the University of Virginia, where he performed research in protein characterization by mass spectrometry. He has spent the last six years working in pharmaceutical development, with the last four of those developing biotherapeutics at Pfizer. He is a principal scientist at Pfizer in their core mass spectrometry group within the “Biotherapeutics Pharmaceutical Sciences” division. For the last three years, he has worked as a member of Pfizer’s multi-attribute method (MAM) team.

Fill out the form to view the free
on-demand webinar

* Required field

*
*
*
*
*
*
*
*
*
 I would like to speak with an expert to learn how Thermo Fisher Scientific products can help in my laboratory.
 Please confirm you would like to receive marketing and promotional email messages about Thermo Fisher Scientific products and services.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.